We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Drug Kinetics – Products

The Biosero logo above the DeepCure logo
Product News

Biosero and DeepCure Collaborate To Establish Fully Automated, AI-Powered Chemistry Synthesis Platform

Biosero, Inc. and DeepCure have announced their collaboration on an advanced, fully automated chemistry synthesis platform to accelerate drug discovery.
A scientist wearing a white lab coat and blue gloves looks at a piece of equipment.
Product News

Sartorius BIA Separations and Exopharm Sign Joint Research Agreement To Develop Integrated Technology for Large-Scale Exosome Production

Sartorius BIA Separations and Exopharm Ltd. have announced they had entered into a formal collaboration.
Thermo Scientific Watson LIMS Software for Bioanalysis – Now on The Cloud content piece image
Product
Advertisement

Thermo Scientific Watson LIMS Software for Bioanalysis – Now on The Cloud

Watson LIMS software, now available on the cloud, is specifically designed and built to support the bioanalytical workflow, allowing users to:
• Harmonize laboratory processes across all sites
• Ease exchange of information between sponsors and contract labs
• Increase throughput by automating data handling and reporting tasks
• Promote compliance throughout the workflow
• Implement quantitative concentration assays or qualitative immunogenicity assays
• Track study sample history from receipt to disposal
RatPlasma
App Note / Case Study

Sensitive Analysis of a PROTAC Degrader in Rat Plasma

Proteolysis targeting chimera (PROTAC) degraders are used to treat drug-resistant targets via targeted protein degradation.
ModDetect™: Detect PS Modifications Independent of Sequence or Location content piece image
Product
Advertisement

ModDetect™: Detect PS Modifications Independent of Sequence or Location

The first of its kind, Rockland’s ModDetect™ Anti-PS Panel consists of specialty antibody reagents developed to detect phosphorothioate (PS) modifications independent of the sequence or location of the modification, making them useful for oligonucleotide therapeutic development, mRNA vaccine development, or research of genetic diseases or gene expression.
ALiS, the latest innovation from Particle Works.
Product News

Particle Works Launches ALiS – An Automated and High-Throughput Platform for LNP Formulation Screening

Particle Works continues to pave the way for particle perfection with the highly anticipated launch of its second revolutionary platform, the Automated Library Synthesis (ALiS) System.
Nine different drug capsules in a horizontal line, each a different colour.
Product News

Lonza Launches New Capsule To Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine

Lonza has launched an innovative new capsule solution for intestinal (enteric) drug delivery.
Microflow Chromatography: A Key to More Sensitive Metabolite Identification content piece image
App Note / Case Study

Microflow Chromatography: A Key to More Sensitive Metabolite Identification

In early-stage pharmaceutical research, knowledge of a compound’s metabolism can assist in the identification of structural liabilities that can contribute to non-optimal pharmacokinetics, potentially toxic breakdown products or the potential for drug-drug interactions.
CapnoPharm Awarded as Drug Delivery Platform Capnodrug® Reaches Finals of Reuters Pharma Europe Award 2022 content piece image
Product News

CapnoPharm Awarded as Drug Delivery Platform Capnodrug® Reaches Finals of Reuters Pharma Europe Award 2022

CapnoPharm is proud to announce its selection as a finalist of the prestigious Reuters Pharma Europe Award 2022 for its Cancer drug delivery innovation - Capnodrug® - in the Health Entrepreneur Award category.
Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration content piece image
Product News

Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration

Avacta Group plc announces that the US Food and Drug Administration has granted Orphan Drug Designation to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.
Advertisement